Payment overview · 2025
General Payments
$31.31
1 reported records · 1 companies
Healthcare provider profile · identity verified
Edward Solis
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1558569335
Verified facts
What the public records show
CMS Open Payments records show Edward Solis received $31.31 in general payments during 2025 across 1 reported records.
ViiV Healthcare Company accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $31.31 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $31.31 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 56 |
| Montelukast Sodium | Montelukast Sodium | 180 | 37 |
| Metformin Hcl | Metformin Hcl | 175 | 47 |
| Omeprazole | Omeprazole | 161 | 40 |
| Lisinopril | Lisinopril | 156 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 27 |
| Gabapentin | Gabapentin | 102 | 28 |
| Trazodone Hcl | Trazodone Hcl | 101 | 22 |
| Losartan Potassium | Losartan Potassium | 85 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 25 |
| Trulicity | Dulaglutide | 77 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Ibuprofen | Ibuprofen | 63 | 13 |
| Famotidine | Famotidine | 61 | 16 |
| Glimepiride | Glimepiride | 61 | 15 |
| Simvastatin | Simvastatin | 61 | 13 |
| Ammonium Lactate | Ammonium Lactate | 57 | 13 |
| Meclizine Hcl | Meclizine Hcl | 56 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 16 |
| Allopurinol | Allopurinol | 49 | 12 |
| Jardiance | Empagliflozin | 48 | 13 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 43 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 43 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Furosemide | Furosemide | 36 | 15 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 22 | suppressed |
| Stribild | Elviteg/Cob/Emtri/Tenofo Disop | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tivicay | Dolutegravir Sodium | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nevirapine Er | Nevirapine | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31.31 · 1 records | ViiV Healthcare Company | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error